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Abstract 
Background: Rheumatic heart disease (RHD) remains the leading cause of cardiac-related deaths and disability in 
children and young adults worldwide. In The Gambia, the RHD burden is thought to be high although no data are 
available and no control programme is yet implemented. We conducted a pilot study to generate baseline data on 
the clinical and valvular characteristics of RHD patients at first presentation, adherence to penicillin prophylaxis and 
the evolution of lesions over time.
Methods: All patients registered with acute rheumatic fever (ARF) or RHD at two Gambian referral hospitals were 
invited for a clinical review that included echocardiography. In addition, patients were interviewed about potential 
risk factors, disease history, and treatment adherence. All clinical and echocardiography information at first presenta-
tion and during follow-up was retrieved from medical records.
Results: Among 255 registered RHD patients, 35 had died, 127 were examined, and 111 confirmed RHD patients 
were enrolled, 64% of them females. The case fatality rate in 2017 was estimated at 19.6%. At first presentation, 
median age was 13 years (IQR [9; 18]), 57% patients had late stage heart failure, and 84.1% a pathological heart mur-
mur. Although 53.2% of them reported history of recurrent sore throat, only 32.2% of them had sought medical treat-
ment. A history suggestive of ARF was reported by 48.7% patients out of whom only 15.8% were adequately treated. 
Two third of the patients (65.5%) to whom it was prescribed were fully adherent to penicillin prophylaxis. Progressive 
worsening and repeated hospitalisation was experienced by 46.8% of the patients. 17 patients had cardiac surgery, 
but they represented only 18.1% of the 94 patients estimated eligible for cardiac surgery.
Conclusion: This study highlights for the first time in The Gambia the devastating consequences of RHD on the 
health of adolescents and young adults. Our findings suggest a high burden of disease that remains largely unde-
tected and without appropriate secondary prophylaxis. There is a need for the urgent implementation of an effective 
national RHD control programto decrease the unacceptably high mortality rate, improve case detection and manage-
ment, and increase community awareness of this disease.
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Introduction
Rheumatic heart disease (RHD) remains the leading 
cause of cardiac-related deaths and disability in chil-
dren and young adults worldwide, with global estimates 
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of more than 34 million people affected and > 345,000 
annual deaths, mainly in Sub-Saharan Africa [1–3]. RHD 
is a chronic complication of acute rheumatic fever (ARF), 
an exaggerated immune response to Group A Streptococ-
cus infections, mostly of the throat, occuring usually dur-
ing childhood and adolescence [4, 5]. RHD complications 
include heart failure, atrial fibrillation, infective endo-
carditis, cardio-embolic stroke and adverse pregnancy 
outcomes [3, 6]. Secondary prophylaxis with 4-weekly 
injection of benzathine penicillin G (BPG) remains the 
most effective intervention for preventing RHD progres-
sion [7]. However, there are numerous and poorly under-
stood barriers to effective control programmes [8].
RHD thrives in poor, over-crowded communities in 
low- and middle-income countries (LMICs) with limited 
access to basic social amenities, including housing and 
health care [1–3]. Despite its high morbidity and mor-
tality, RHD became largely neglected after it was virtu-
ally eliminated in high-income countries (HICs) by the 
end of the twentieth century [9]. In May 2018, follow-
ing years of campaigning and advocacy from the RHD 
community [10] the World Health Organisation (WHO) 
launched the “Global Resolution on Rheumatic Fever 
and Rheumatic Heart Disease” which was unanimously 
adopted by member states [11]. This resolution calls for 
action to strengthen primary and secondary prevention 
of ARF and RHD, integrate RHD services into primary 
health care, secure a reliable supply of BPG, and ensure 
a well-resourced and trained health workforce to provide 
RHD services. Indeed, the main barriers to RHD preven-
tion, control and elimination in endemic countries are: 
the neglect of ARF and RHD in national health policies 
and budgets; the paucity of data to enable targeting of 
prevention efforts; poor primary and secondary preven-
tion and access to primary health care; inadequate num-
bers and training of health workers at all levels; limited 
understanding of ARF/RHD in affected communities, 
and inaction on the social determinants of the disease 
and inequities in health [11]. Although further research 
in some areas is needed, the biggest gap in RHD control 
is in the implementation of effective primary and second-
ary preventive measures. On 6th January 2020, the World 
Heart Federation (WHF) President met with the WHO 
Director General to share ambitions and actions which 
would lead to the elimination of RHD in a generation [11, 
12].
In The Gambia, the burden of RHD is thought to be 
high given the substantial number of children presenting 
at referral hospitals at an advanced stage of the disease. 
Indeed, there are more than 250 children with RHD cur-
rently being managed as outpatients at the paediatrics 
department of the Edward Francis Small Teaching Hospi-
tal (EFSTH), the main referral and only teaching hospital 
in The Gambia, and at the Clinical Services Department 
(CSD) of the Medical Research Council Unit The Gambia 
at the London School of Hygiene and Tropical Medicine 
(MRCG). Despite this, no high-quality data are available 
and no control programme is currently implemented.
In both institutions, care for children with RHD 
(including consultation, laboratory, imaging and medi-
cations) is provided free of charge. Echocardiography is 
available at the MRCG and is provided free of charge for 
children while adults are charged ~ US$4. There are three 
private echocardiography service centres, all of them 
based at the coast near the capital city, whose services are 
charged $30 to $40 per patient.
As a first step towards larger, collaborative, multi-dis-
ciplinary research projects between the Gambian Health 
Services and the MRCG to inform the development of 
an effective national RHD control programme, we con-
ducted a baseline study to review all patients registered 
as having ARF or RHD at the MRCG and/or EFSTH. The 
objective was to describe the clinical and valvular char-
acteristics of known RHD patients at first presentation, 
at last evalution during the present study, adherence to 
penicillin prophylaxis and the evolution of clinical and 
valvular lesions over time.
Methods
Study design and patients recruitment
This case series analysis was carried out between Novem-
ber 2017 and January 2018 and included children and 
adult patients (all age) with ARF or RHD registered at 
two referal hospitals in the Gambia, i.e. the MRCG CSD 
in Fajara or the paediactrics department of the EFSTH in 
Banjul. A list of patients currently or previously (within 
the last 3  years) treated for ARF or RHD was gener-
ated and individual patients contacted (or their parents/
guardians for children < 18) by telephone. The MRCG 
has an electronic medical records system (EMRS) which 
enabled a quick search using ARF or RHD as keyword 
for provisional/definitive diagnosis. At the EFSTH, the 
clinical records were searched manually. Patients were 
called individually by the study nurse who explained the 
project’s objectives and invited them to participate in the 
study. Several call attempts were made before declaring 
a patient unreachable. Patients were invited based on 
their availability, to attend the MRCG CSD for clinical 
evaluation.
Data collection
Written informed consent was obtained from all partici-
pants, or their parents/guardians for children < 18 years, 
after detailed information on the study objectives and 
procedures was provided by the study team in English 
or one of the local languages (Mandinka, Wolof, Fula). 
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Children aged 12–17 years were invited to provide their 
written assent. A questionnaire was administered on 
socio-demographic characteristics, past medical history, 
including signs and symptoms at first presentation, treat-
ments received and current symptoms, e.g. shortness of 
breath at rest or on exertion. Patients’ medical records 
(when available) were also searched to extract past medi-
cal history.
Vital signs at rest, i.e. heart- and respiratory rates, 
blood pressure (Omron sphygmomanometer), axillary 
temperature (digital thermometer), oxygen saturation 
(pulse oximeter), were measured by the study nurse; and 
a detailed physical examination was perfomed by a medi-
cal doctor, including cardio-thoracic auscultation and 
assessment for signs of right heart failure (hepatomegaly, 
lower limb oedema). Heart failure was classified into four 
categories according to the Modified Ross Score for chil-
dren or the New York Heart Association in adults [13].
Until April 2013, secondary prophylaxis for RHD in 
The Gambia consisted of monthly injections of Ben-
zathine Penicillin G (BPG) until the age of 20  years for 
patients with valvular lesions. This was changed to daily 
oral penicillin V (250  mg BID for children < 30  kg or 
500 mg if > 30 kg) following a few sudden deaths shortly 
after BPG injection that suggested an anaphylactic reac-
tion and/or sub-standard quality drugs [14, 15]. The 
duration of secondary prophylaxis with penicillin V was 
unchanged until the time of our study.
Echocardiography protocols and image interpretation
Each patient was subjected to a 2D, M-mode, colour and 
spectral Doppler transthoracic echocardiography by the 
study cardiologist using a Vivid IQ (General Electrics) 
portable echo machine. Multifrequency phase array 
transducers (paediactric and adult) with a frequency 
range of 3—6  MHz were used. A 6-image acquisition 
protocol was used with focus on valve pathology & func-
tion as well as cardiac chamber size and function (atria 
and ventricles). This protocol included the parasternal 
long- and short axes views, apical four-chamber, two-
chamber & three-chamber views as well as subcostal long 
axis view in 2D and colour Doppler. In addition, continu-
ous wave Doppler across the mitral and tricuspid inflow, 
and aortic and pulmonary outflow were measured if any 
of these valves showed evidence of regurgitation or ste-
nosis. RHD was classified as bordeline or definite (mild, 
moderate or severe) according to the severity of the 
most affected valve following the WHF consensus crite-
ria [16]. External quality control of the echocardiogra-
phy readings was done by an independent cardiologist 
at INSERM, Paris, France. All anonymised images were 
shared via the cloud using the DICOM platform (https:// 
www. postd icom. com/). Discrepant results (difference in 
either diagnosis and/or in severity of the lesion at any of 
the four valves) were reviewed and discussed by the two 
readers (via email) until agreement was found. The final 
data analysis included only patients with confirmed RHD. 
Cases with normal echocardiography, non-RHD cardiac 
disease, or other alternative diagnoses were excluded.
Data analysis
Socio-demographic, clinical and echocardiography data 
were entered and cleaned in a REDCap online database, 
and analysed in STATA 12. Summary statistics were 
computed and differences were tested for statistical sig-
nificance (p < 0.05) using Student t-test for continuous 
variables and Chi-square or Fisher Exact accordingly for 
categorical variables.
Socio-economic status (SES) was categorized as high, 
medium or low according to the following facilities/
assets the patient’s household had or owned: pipewater, 
gas, electricity, fridge, TV, motorbike, vehicle (tractor, 
truck, car). The lowest SES category included households 
that had none of the above mentioned items while the 
highest category included households with at least a vehi-
cle regardless of the other items; the medium SES cate-
gory included all the remaining households. We included 
all forms of Western education (French/English/German, 
etc.) recognized as formal education in The Gambia but 
excluded Arabic/Quranic schooling.
Treatment adherence since first presentation was 
categorized according to the patient’s (and/or parent/
guardian’s) own report and his/her medical records as: 
(i) full (= regular intake with rare interruption); (ii) par-
tial (= regular intake with occasional interruptions), (iii) 
poor (irregular intake), (iv) and very poor (very irregular 
intake with prolonged (> 1 week) voluntary interruption). 
Patients who had deliberately stopped penicillin prophy-
laxis for more than one month at the time of the study 
visit were categorized as defaulters. No attempt was 
made to verify treatment adherence using pill counts or 
other measures. We tested if adherence was significantly 
associated with any potential risk factor (i.e., age at pres-
entation, sex, SES, mother’s education, follow-up time, 
household crowdedness, or the Ross score at presenta-
tion) using Fisher Exact- or Chi-square test accordingly 
(signficant p-value < 0.05). For this purpose, continous 
variables were categorized (i.e., age categories: 0–10; 
11–19; 20+ years; and length of follow-up categories: < 5-, 
5–9; 10+ years).
The evolution of valvular lesions (for patients who had 
a report on their first echocardiography and not under-
gone cardiac surgery) were assessed and categorized as 
follows: (i) no change (same lesions and severity as in 1st 
echo-); (ii) initial lesions decreased (current lesions were 
less severe or disappeared compared to 1st echo-); (iii) 
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initial lesions worsened (new lesions appeared and/or 
initial lesions increased in severity).
The association between valvular or clinical evolu-
tion and potential risk factors was explored using Fisher 
Exact- or Chi-square test accordingly (patients with sur-
gery were excluded from this analysis). Significant trends 
were tested using the z-test for trend.
We estimated the number of reviewed cases in need 
of cardiac surgery based on the severity of the valvu-
lar lesions (severe mitral stenosis and/or regurgitation, 
severe aortic stenosis and/or regurgitation, severe tricus-
pid regurgitation—mostly functional) and other echo-
cardiographic findings such as reduced left ventricular 
systolic function (LVEF < 40%) and severe secondary 
pulmonary hypertension (Estimated Pulmonary Arterial 
Systolic Pressure > 60 mmHg) [17–20].
Ethical considerations
Ethical approval was obtained from the Gambia Govern-
ment/MRC Joint Ethics Committee (L2017.56). Permis-
sions were given by the Gambian Health Services, the 
EFSTH in Banjul and the CSD of the MRCG in Fajara.
Results
Patients’ recruitment and RHD mortality
Among the 255 eligible patients with provisional diag-
nosis of RHD, 52 (20%) could not be traced, 35 (13.7%) 
had died, 30 (11.8%) refused to participate, and 11 (4.3%) 
did not attend the scheduled visit (Fig.  1). Among the 
127 patients examined, 16 were excluded from the anal-
ysis as they did not meet the RHD case definition, and 
111 patients with confirmed RHD by standard echocar-
diography were enrolled (Fig. 1). The medical records of 
the deceased patients were reviewed and most of them 
(30/35 = 85.7%) were ≤ 25  years old with similar num-
bers of males and females (sex ratio M/F 18/17 = 1.1). 
The majority died in 2017 (27/35 = 77%) while admitted 
for heart failure. The case fatality rate in 2017 was esti-
mated at 19.6% (27/138) when considering the 111 RHD 
patients plus the deceased (N = 111 + 27 = 138).
Baseline socio‑demographic data
Between November 6th, 2017 and January 3rd, 2018, 
a total of 111 patients (100 at MRCG and 11 at the 
EFSTH) were reviewed clinically and echographically 
and confirmed RHD. The majority were females (64%) 
and the median age was 16  years (IQR [13; 24]). Most 
patients (77.5%) were either in- or had some level of 
formal schooling but the majority (65.8%) had a mother 
without formal education (Table 1). About a fifth of the 
patients (21.6%) belonged to the poorest socio-economic 
category, and households were generally crowded with 
a median of 9 dwellers (IQR [6; 14]). Very few patients 
slept alone in a room (median of 2 additional persons) or 
in a bed (median of 1 additional person) (Table 1).
Disease history (Table 2)
The median follow-up time since first presentation 
was 33  months (IQR[3;121]) ranging from 1  month 
to 12  years. The median age at first presentation was 
13  years (IQR [9; 18]) though 30 patients (27.0%) were 
first diagnosed with RHD at adult age, among whom 21 
were women diagnosed only after up to 9 vaginal deliv-
eries as they went into heart failure. Their first echocar-
diogram showed severe valvular lesions often associated 
with pulmonary hypertension.
About half of the 111 patients (53.2%) reported a his-
tory of recurrent sore throat for which only 19 (32.2%) 
had attended a health facility. Most patients did either 
nothing or used traditional medicine, usually drinking 
hot water with lime and pepper or with salt. Moreover, 
about half of the patients (48.7%) reported one or more 
episodes of fever associated with joint pain and swell-
ing compatible with ARF. Although the majority (38/54, 
70.4%) attended a primary or secondary health care facil-
ity, only 6 (15.8%) were actually diagnosed and treated for 
Excluded (not RHD)=16
- Normal=4
- Congenital heart disease=2
- Congestive cardiac failure=1, 
- Hypertensive heart disease=1, 
- Peripartum cardiomyopathy=1


















Fig. 1 Flowchart showing the recruitment of participants
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ARF while the others received painkillers and antibiotics. 
Recurrent skin sores (e.g. impetigo, folliculitis) were less 
commonly reported (< 20% of the patients) but generally 
medically attended.
Clinical and valvular characteristics at first presentation
Among the 107 patients with available data from first 
presentation, 61 (57%) had symptoms of late stage heart 
failure (Modified Ross/NYHA score 3–4) and a third 
(33.6%) had a score of 2 (Table 2). Most patients (84.1%) 
had a pathological heart murmur at auscultation, mainly 
a grade III–IV pan-systolic murmur at mitral area, and 
43% presented with lower limb oedema of whom 30% 
with anasarca (Table  2). A written report on baseline 
echocardiography was available for 93 patients among 
whom 86 had some measured parameters to be com-
pared with those measured during our review (Table 4). 
On their first echocardiogram, all but five patients had 
thickened valves (MV) with restricted mobility and/or 
a prolapse of the anterior mitral valve leaflet (Table  4). 
Table 1 Socio-demographic characteristics of study patients
Characteristics (N = 111) N %
Gender
 Males 40 36
 Females 71 64
Age, median [IQR] 16 [13;24]
Residence
 Costal districts (Kombos, Banjul, Kanifing, Barra town) 97 87.4
 Others (included 1 Casamance, 2Fara, 1 Basse, 1Bansang 14 12.6
Moved to Kombos since diagnosis 10 9
Ethnic groups
 Mandinka 49 44.1
 Wolof 12 10.8
 Fula 14 12.6
 Jola 17 15.3
 Others (Sarahule, Manjago, Serere) 19 17.1
Education level
 Currently following formal schooling 50 45.1
 Previous primary schooling 20 18
 Previous secondary schooling 16 14.4
 Exclusive Arabic/Quranic schooling 9 8.1
 Never had any schooling 16 14.4
Education level of the mother
 None 15 13.5
 Primary school 20 18
 Secondary school 18 16.2
 Exclusive Arabic/Quranic schooling 58 52.3
Socio economic status
 Poorest 24 21.6
 Medium 48 43.2
 Higher 39 35.1
Patients’ households crowdeness
Persons per households, median [IQR] 9 [6;14]
Patients’ sleeping room arrangements
 Patient sleeps alone in the room 6 5.4
 Median number of other individuals sleeping in the room, [IQR] 2 [1;4]
Patients’ bed sleeping arrangements
 Patient sleeps alone in his bed 9 8.1
 Median number of other individuals sleeping in the bed, [IQR] 1 [1;2]
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Most patients (80/86 = 93.0%) had MV regurgitation, 
mainly severe (58.8%), while 22 (22/86 = 25.6%) had 
mitral stenosis, mostly severe (68.2%), and gener-
ally associated with mitral valve regurgitation (MVR; 
17/22 = 77.3%). More than half of the patients (54.7%) 
had aortic regurgitation including three with both aortic 
regurgitation and stenosis. TV regurgitation was com-
mon (63/86 = 73.3%) though mostly functional (due to 
annular dilatation) while pulmonary valve (PV) regurgi-
tation was less commonly found (17/86 = 19.8%). More 
Table 2 Clinical characteristics at first presentation (Day 0)
Characteristics N %
Median follow-up time (months since 1st presentation, N = 87) [IQR] 33 [3;121]
Median age, [IQR] 13 [9;18]
History of recurrent sore throat
 Yes 59 53.2
 No 52 46.8
Usual treatment for sore throats (N = 59)
 No treatment at all 11 18.6
 Traditional medicine (hot water w. salt/lime/pepper,…) 27 45.8
 Self-treatment (buy medicines, don’t know what) 2 3.4
 Consulted health facilities 19 32.2
Reported history of acute rheumatic fever (ARF) 54 48.7
Treatment for ARF (N = 54) 38 70.4
 Consulted health facilities 15 27.8
 Traditional treatment 1 1.8
 No treatment
History of skin sores
 Yes 20 18
 No 91 82
Modified Ross or NYHA Score (N = 107)
 Class 1 (no dyspnea) 10 9.3
 Class 2 (dyspnea, fatigue on moderate exertion) 36 33.6
 Class 3 (dyspnea, fatigue on minimal exertion) 22 20.6
 Class 4 (dyspnea at rest) 39 36.4
Oedema lower limbs (N = 107)
 No 61 57
 Yes (30% Grade 4) 46 43
Heart murmur at auscultation (N = 107)
 No 14 13.1
 Yes 90 84.1
 Missing 3 2.8
Enlarged liver (N = 107)
 No 63 58.9
 Yes 19 17.8
 Missing 25 23.4
Penicillin prophylaxis started upon RHD diagnosis
 No 17 15.3
 Yes 93 83.8
 Missing 1 0.9
Anti-heart failure treatment needed at first presentation
 No 23 20.7
 Yes 86 77.5
 Missing 2 1.8
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than a third (33/86 = 38.4%) of the patients had pul-
monary hypertension at first presentation and 8% had 
impaired left ventricular systolic function.
Penicillin prophylaxis and adherence
The majority of patients (n = 93) were started on penicil-
lin prophylaxis (PP) upon RHD diagnosis (i.e., monthly 
BPG injections before April 2013 (n = 25) and later, twice 
daily oral penicillin V (n = 68); Table  2). At the time of 
our review, 22 patients (23.7%) were no longer under PP 
including 16 who defaulted for up to 3 years, and 6 whose 
PP was appropriately stopped by the prescriber based on 
previous national guidelines. Among the 71 patients still 
on PP, 57 were classified as fully adherent, while the rest 
were occasionally or regularly missing their daily penicil-
lin doses.
Penicillin adherence was estimated among patients 
who had started penicillin and were either still taking it 
or had spontaneously defaulted at the time of the review 
(71 + 16 = 87). Overall, about two third (65.5% = 57/87) 
of patients were estimated fully adherent and thus con-
sidered as effectively protected. No significant association 
was found between adherence and age at presentation, 
sex, socio-economic level, mother’s education, follow-up 
time, household crowdness, or the Ross score at presen-
tation (all Fisher Exact p-values > 0.10).
Clinical and valvular evolution since 1st presentation
The median follow-up time since first presentation was 
3 years (IQR[< 1y; 11]). Most of the 111 patients were sta-
ble at the time of the review as 93.7% scored 1 to 2 on 
the Modified Ross/NYHA Score (Table  3). Seventeen 
patients had undergone cardiac surgery abroad, includ-
ing 9 mitral valve repairs and 8 mechanical mitral valve 
replacements treated with lifelong warfarin. Post-oper-
ative complications were rare, the main issue being the 
adherence to the daily dose of warfarin and the monthly 
monitoring of international normalized ratio (INR), 
though there was only 1 case of intracranial bleeding, and 
no thrombotic complications recorded. At the time of 
review, about half of the patients (59/111 = 53.2%) were 
stable either without- or after initial antifailure treatment 
(Table 3). The other half (52/111 = 46.8%) of the patients 
had regular worsening of their condition, with repeated 
hospital admissions, including those who had cardiac 
surgery. No significant association was found between 
the clinical evolution and sex, age at first presentation, 
socio-economic level, Ross score at presentation, or 
adherence to penicillin (all Fisher Exact p-values > 0.10). 
Clinical evolution was significantly associated with time 
since first presentation (Exact p = 0.03) with a significant 
trend of worsening evolution with increasing follow up 
time (categorized as < 5y, 5–9y, ≥ 10y) (z-test for trend 
p = 0.012). There was also a significant trend between 
lower mother education and worsening clinical evolution 
(z-test for trend p = 0.04).
Standard echocardiography results from the 94 patients 
who didn’t undergo cardiac surgery are summarized in 
Table 4. All patients had dysmorphic MV features asso-
ciated mainly with a MV regurgitation (79 = 84.0%). 
Twenty five patients had MV stenosis mostly severe (64%) 
and associated with MVR (16/25, 64.3%). More than half 
of the patients had an AVR (48/94 = 51.1%), 53 (56.4%) 
had functional TVR, and 28 (29.8%) had mild pulmo-
nary regurgitation. More than a third (34/94 = 36.2%) 
of the patients had pulmonary hypertension and 13 
(13/94 = 13.7%) had impaired systolic function.
The evolution of valvular lesions could be assessed 
in 73 patients for whom measurements were avail-
able for their first echocardiography. The median time 
elapsed since first echocardiography was 20  months 
(IQR[4;112]). Valvular lesions were unchanged in 58.9% 
(43/73) patients, had worsened in 23.3% (17/73) and 
regressed in 17.8% (13/73) patients. The valvular evolu-
tion was not significantly associated with sex, age at first 
presentation, severity of initial lesions, clinical evolution, 
duration of follow-up, adherence to PP (all Exact Fisher 
p-values > 0.05).
Based on the severerity of valvular lesions, cardiac 
function and pulmonary hypertension at the time of our 
review, it was estimated that 77 patients would have been 
eligible for heart surgery in addition to the 17 who had 
this opportunity, hence the vas majority (17/94 = 81.9%) 
of the cardiac surgery need was not covered.
Discussion
“This is the first publication of the RHD burden in 
The Gambia, reporting on the clinical and valvular 
evolution of RHD with related challenges to effec-
tive penicillin prophylaxis in a retrospective cohort 
of 111 RHD patients. While documenting a high 
burden, we have detected only those who presented 
to the health care system, largely with symptoms of 
heart failure suggesting severe disease. These find-
ings suggest that there are many more cases of unde-
tected disease, particularly in adolescents and young 
adults. For example, in Australia where RHD regis-
tration is the most comprehensive in the world, only 
19% of cases are severe, 28% are moderate and 53% 
are mild [21]. Hence in the Gambia the true RHD 
burden is likely several-fold higher than reported 
here. This first Gambian report allowed us to high-
light key challenges (Fig.  2) to be addressed for the 
control and elimination of RHD in a generation [12, 
22, 23].”
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It is important to highlight the high case fatality rate, 
particularly in young patients, in the face of unavailable 
cardiac surgery in the country. Our case fatality rate in 
2017 was estimated at almost 20% and this was similar 
(17.8%) to the one reported the same year in a prospec-
tive cohort study conducted in Uganda by Okello et  al. 
[24]. The REMEDY study which compiled data from 14 
LMICs between 2010 and 2012 reported a 2-year case 
fatality rate of 16.9% [25]. A prior study conducted in 
Ethiopia in 2005 reported an annual case fatality rate of 
12.5% [26]. These data highlight what has been described 
elsewhere as the”stark reality of rheumatic heart disease” 
in Africa [27], and other developing countries [28, 29]. 
Most of our patients (86%) died before their 25th birth-
day, at a median age of 17 years, showing the high human 
and socio-economic burden of premature deaths in The 
Gambia. This calls for the urgent implementation of 
effective control measures to achieve by 2025 the WHF 
strategic goal of reducing by 25% RHD mortality in indi-
viduals aged < 25 years [8].
The high case fatality rate is consistent with the finding 
that most patients only seek health care at an advanced 
stage of heart failure (Ross 3–4) and severe mitral valve 
Table 3 Clinical characteristics at review and adherence to penicillin prophylaxis
Characteristics N %
Median heart rate, IQR (n = 111) 4 patients with AF 85 [74;92]
Normal  O2 saturation 110 99.1
Patients with tachycardia (> 100/min if age > 11; > 120 if <  = 11) 10 9
Modified Ross classification
 Class 1 35 31.5
 Class 2 69 62.1
 Class 3 6 5.4
 Class 4 1 0.9
Pathological murmur at auscultation
 No 9 8.1
 Yes 102 91.9
Chest auscultation
 Abnormal 11 9.9
 Normal 98 88.3
 Missing 2 1.8
Oedema lower limbs
 No 107 96.4
 Yes (3 grad2, 1 grad3) 4 3.6
Enlarged liver
 No 102 91.9
 Yes 9 8.1
Still under penicillin prophylaxis (N = 93)
 No 22 23.7
 Yes 71 76.3
Overall estimated adherence to penicillin prophylaxis (N = 87)
 Defaulters and poorly adherent 19 21.8
 Regular intake with occasional missed doses 11 12.6
 Fully adherent (rare missed dose) 57 65.5
Clinical evolution since diagnosis (n = 111)
 Patient stable without anti-failure treatment (including 7 defaulters) 17 15.3
 Good response to initial anti-failure therapy, now stable 42 37.8
 Slight worsening, with adjustment of initial treatment, now stable; 19 17.1
 Regular worsening with adjustements of antifailure therapy; 10 9
 Serious worsening with repeated hospital admissions; 6 5.4
Cardiac surgery 17 15.3
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lesions are often associated with other valvular lesions. 
This is a common finding in RHD endemic coun-
tries. Indeed, in Uganda, 85% of newly diagnosed RHD 
patients at the national referral hospital had cardio-
vascular symptoms and half of them had complications 
such as congestive cardiac failure, including 32.7% with 
Table 4 Echocardiography characteritistics at presentation (baseline) and at review (17 patients with cardiac surgery excluded)
Baseline (N = 86) Review (N = 94)
Characteristics N % Characteristics n %
MV regurgitation (N = 80) MV regurgitation (N = 79)
 Mild 13 16.2  Mild- 12 15.2
 Moderate 15 18.8  Moderate- 12 15.2
 Severe 47 58.8  Severe- 55 69.6
 Not specified 5 6.2
MV stenosis (N = 22) MV stenosis(N = 25) (10 isolated, no MVR)
 Mild 4 18.2 Mild 2 8
 Moderate 2 9.1 Moderate 7 28
 Severe 15 68.2 Severe 16 64
 Not specified 1 4.5
AV regurgitation (N = 47) AV regurgitation (N = 48)
 Mild 18 38.3  Mild 11 22.9
 Moderate 14 29.8  Moderate 21 43.8
 Severe 12 25.5  Severe 16 33.3
 Not specified 3 6.4
AV stenosis (N = 3 = 1 mild & 2 severe) AV stenosis (n = 1 moderate in 4 valves dysfunction)
TV regurtation (N = 63) TV regurgitation (N = 53)
 Mild 19 30.2  Mild 18 33.9
 Moderate 22 34.9  Moderate 18 33.9
 Severe 20 31.7  Severe (including 1 severe TVS) 17 33.1
 Not specified 2 3.2
Pulmonary valve (PV) regurgitation 17 19.8 Pulmonary valve (PV) regurgitation (all mild) 28 29.8
 Mild 12 70.6 Impaired LV systolic function (EF < 55%) 13 13.8
 Moderate 2 11.8 Pulmonary hypertension (ePASP > 40 mmHg) 34 36.2
 Severe 1 5.9 Pericardial effusion 5 5.3
 Not specified 2 11.8 Valvular evolution (vs baseline; N = 73 available)
Impaired LV systolic function (EF < 55%) 7 8.1  No change 43 58.9
Pulmonary hypertension (ePASP > 40 mmHg) 33 38.4  Initial lesions decreased 13 17.8
Pericardial effusion 3 3.5  Initial lesions worsened 17 23.3
1. The case fatality in 2017 was estimated at 15-20% affecting mainly patients aged 25 years or less;  
2. The majority of patients presented very late with advanced stage heart failure and severe multiple 
valve lesions; 
3. Two third of the patients with recurrent sore throat missed the opportunity of primary prevention 
using approprite antibiotic treatment;  
4. About half of the patients reported a history of likely rheumatic fever which was rarely 
recognized and treated accordingly by primary health care staff; 
5. Adherence to daily oral penicillin was difficult with less than 50% of the patients eligible for 
penicillin prophylaxis effectively taking it regularly and 30% were not adherent at all;  
6. There is a crucial lack of access to cardiac surgery in West Africa. Only 15% of patients 
examined had benefited from surgery while this was deemed necessary in 85% of them;   
Fig. 2 Key learning points from this study
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pulmonary hypertension [30]. In a later cohort study [24] 
Okello et  al. also showed that both morbidity and mor-
tality were significantly higher in patients presenting late 
with advanced disease. Similar characteristics at pres-
entation were reported by the multi-country REMEDY 
study [25]. In another report of the REMEDY study [6] 
atrial fibrillation was documented in 21% of the patients; 
stroke, systemic embolism, bleeding and infective endo-
carditis were reported in all countries.
The main reason for late presentation in LMICs is 
the limited understanding of ARF and/or RHD in the 
affected communities [31, 32]. In our study, history of 
recurrent sore throat was reported by more than half of 
the patients but only a few of them had sought medical 
treatment, missing the opportunity for primary prophy-
laxis of ARF. Most patients were unaware of the link 
between sore throat, ARF and RHD, and believed tradi-
tional remedies were more appropriate. This has already 
been observed in other endemic countries, both within 
[33–35] and outside [36–38] Africa. Interestingly, about 
half of our patients reported a history of ARF before 
developing signs of heart failure and most of them had 
consulted a health facility. Unfortunately, this oppor-
tunity for secondary prophylaxis was missed by the 
local health staff as only 6 patients were diagnosed and 
treated for ARF. This is not surprising as ARF is usually 
underdiagnosed in endemic settings [3, 30, 35, 36]. ARF 
remains a diagnostic challenge for most clinicians due to 
the multi-systemic nature of the condition and diversity 
in presentations [39]. The diagnosis of ARF, given the 
high occurrence of atypical presentations, is often based 
on clinical suspicion. Treatment should be started with-
out delay to avoid misdiagnosis, the risk of disease pro-
gression and cardiac sequelae. In The Gambia, primary 
health care staff (mostly nurses) are usually unaware of 
the moderate to high risk of ARF/RHD in local com-
munities. This explains their low level of suspicion when 
dealing with aseptic mono-arthritis, polyarthralgia or 
sub-clinical carditis, a relatively common occurrence [39, 
40]. Such a problem has been internationally recognized 
and the 2015 revision of Jones Criteria now includes 
echocardiographically diagnosed subclinical endocardi-
tis as a major criterion and recommends echocardiogra-
phy in all proven and suspect cases [41, 42]. About half 
of our patients reported signs and symptoms compat-
ible with ARF, offering the opportunity to improve sec-
ondary prophylaxis if health staff are adequately trained. 
This calls for an urgent update of the current medical 
and nursing curricula to improve ARF case management 
and provide a more accurate estimation of the ARF/RHD 
burden.
A few of our patients were diagnosed with heart 
failure during adulthood. These were predominantly 
women, about half of them multiparous, with multi-
ple severe valvular lesions, often including mitral valve 
stenosis, and pulmonary hypertension. This suggests 
a different pattern of evolution, compared to patients 
diagnosed during childhood, as RHD lesions may have 
developed at sub-clinical level very slowly, allowing the 
heart to progressively adapt to new valvular lesions and 
cope with related hemodynamic changes until decom-
pensation, i.e. after several pregnancies. The physiolog-
ical hemodynamic changes during pregnancy, including 
increased stroke volume, heart rate and cardiac output, 
are poorly tolerated in patients with rheumatic valve 
disease. Indeed, in LMICs, RHD is the most frequent 
cardiac condition during pregnancy and the first cause 
of maternal death [43–45]. A recent international reg-
istry study on 390 pregnant women has shown that 
women with moderate, severe or symptomatic rheu-
matic mitral valve disease, especially those with severe 
mitral stenosis, are at very high risk of heart failure 
during pregnancy, while those with mild or asymp-
tomatic mitral valve disease tolerated pregnancy well 
[46]. Systematic screening for RHD among pregnant 
women in LMICs, especially primigravidae, could sig-
nificantly improve the pregnancy outcomes and the 
prevention of further valve damage with adequate sec-
ondary prophylaxis.
Secondary penicillin prophylaxis is essential for the 
management of ARF and the prevention of recurrences 
[7] and intramuscular BPG is superior to oral penicil-
lin. Secondary prophylaxis reduces the severity of RHD 
by preventing disease progression [47, 48], and even 
by increasing the rate of regression of mitral regurgi-
tation. Since 2013, our patients were given oral sec-
ondary PP although only half of them were taking it as 
recommended. This is not surprising given that in RHD 
patients with persistent valvular disease oral penicil-
lin should be taken twice daily at least until the age of 
40  years [49]. It is difficult to estimate adherence retro-
spectively as this may vary over time and patient’s age. 
Indeed, some patients adhered strictly to the treatment 
for several years before defaulting. The main reported 
reasons for low adherence or defaulting among children 
were either financial constraints (transport costs for 
monthly reviews, or costs for medicine following regular 
drug shortages), lack of time or motivation of the par-
ents/caretaker for monthly reviews, or the geographi-
cal distance from the clinic. Adherence to monthly BPG 
injections may not necessarily be better as it has other 
disadvantages (i.e. pain, fear of anaphylactic shock) [50]. 
Interventions to improve adherence to secondary proph-
ylaxis should consider several factors, e.g. age, socio-
cultural factors, and the health system capacity and may 
include an active recall system, provision of holistic care, 
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involvement of community health workers and delivery 
of ARF/RHD health education.
“Although valvular lesions worsened in less than 
25% of our patients, such estimation does not 
include those who died (n=35) and those who 
underwent surgery (n=17). This proportion can also 
be explained by the fact that most of our patients 
presented with already severe valvular disease. Con-
cerning the clinical evolution of the 111 patients, 
almost half of them showed some degree of worsen-
ing since presentation.”
. In our context, this is likely due to the combination 
of late presentation leading to unfavorable outcomes [24, 
51], and poor adherence to secondary prophylaxis. There-
fore, in The Gambia BPG should be recommended for 
both primary and secondary prophylaxis. However, given 
the past history of sudden deaths and current fear of ana-
phylactic shock, many health care workers still feel anx-
ious about its use. Therefore, we need substantial health 
education and training about the safe delivery of intra-
muscular BPG for both primary and secondary prophy-
laxis. Experience from other countries have shown that 
improved delivery of BPG can be achieved and results in 
good adherence by patients [50, 52, 53].
Cardiac surgery is not available in The Gambia, there-
fore only a very small proportion of RHD patients can 
benefit from it abroad with the support of private spon-
sors. The international non-governmental organization 
(NGO) “Chain of Hope” (https:// www. chain ofhope. org/) 
has been supporting cardiac surgery for Gambian chil-
dren since 2007 but only 3–5 children on average per year 
are selected. On a positive note, the recent development 
of cardiac surgery in neighboring Senegal may improve 
access in the near future to life-saving interventions for 
our young Gambian patients.
The study had some important limitations due to the 
retrospective data collection. First, the study design (hos-
pital-based retrospective cohort) did not allow estimating 
the RHD burden in the local communities. However, the 
high number of RHD patients presenting at an advanced 
stage of heart failure and the fact that some of them are 
diagnosed during adulthood, particularly multigravidae, 
suggests a high and largely undetected burden of RHD.
Secondly, the absence of EMRS and specific record 
keeping for ARF/RHD patients at the Teaching Hospital 
led to an under-representation of their patients (i.e. only 
10 versus 101 patients from MRCG) while they are both 
referral centers. However, clinical and valvular charac-
teristics at first presentation, evolution, poor access to 
cardiac surgery and high mortality are probably similar 
across institutions.. Adherence to penicillin, as well as to 
anti-failure treatment, might be slightly worse at ESFTH 
as compared to MRCG, due to frequent stockouts, 
requiring patients to buy treatment in private pharmacies 
outside the hospital.
Selection bias may have occurred as only 111 con-
firmed RHD patients out of the initial 255 RHD regis-
tered patients (43.5%) were examined and the severity 
of lesions at presentation, adherence to penicillin and 
evolution over time may have been different among non-
included patients. It is difficult to speculate how the bias 
would have influenced the results as the refusal to par-
ticipate may be related to severity of disease, e.g. severely 
sick or asymptomatic. Moreover, non traced patients may 
have died and this would increase the case fatality rate. 
Nevertheless, our estimated case fatality rate is compa-
rable to other prospective cohort studies in LMICS, sug-
gesting minimal bias, if any. Our case series represents 
a “survivors cohort” and hence is more representative 
of surviving patients than of all RHD patients. There-
fore, prospective cohort studies are urgently needed to 
adequately assess the clinical and valvular evolution, and 
adherence to penicillin prophylaxis and case fatality of 
RHD.
This study highlights for the first time the devastating 
consequences of RHD on the health of Gambian adoles-
cents and young adults. Our findings suggest a high and 
largely undetected burden of disease that is not addressed 
by appropriate secondary prophylaxis. There is a need for 
the urgent implementation of an effective national RHD 
control program to decrease the unacceptably high mor-
tality rate, improve case detection and management, and 
increase community awareness of this disease. As rec-
ommended by the World Heart Federation, The Gambia 
needs a national RHD registry based on echocardiogra-
phy screening (including pregnant women), the provision 
of safe and high quality BPG, and improved access to car-
diac surgery in order to achieve the “25 by 25” strategic 
goal.
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